Last reviewed · How we verify
NCT04856137: DLBL
A Phase I/II Study of Diffuse Large B-cell Lymphoma
Phase 1, PHASE2 trial testing Rituximab Paclitaxel Ruxolitinib in Refractory Diffuse Large B-cell Lymphoma in 74 participants. Not yet recruiting.
31 December 2023
Quick facts
| Lead sponsor | National Health Research Institutes, Taiwan |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 1 May 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2028 |
Drugs / interventions tested
- Rituximab Paclitaxel Ruxolitinib — full drug profile →
Conditions studied
- Refractory Diffuse Large B-cell Lymphoma — all drugs for Refractory Diffuse Large B-cell Lymphoma →
Sponsor
National Health Research Institutes, Taiwan
Who can join
Adults 20 to 75, any sex, with Refractory Diffuse Large B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
For continuous variables, mean, median, minimum, and maximum will be used for the descriptive purpose. For categorical variables, frequency and percentage will be used for descriptive statistics. The variables of OS will be estimated by the Kaplan-Meier method. Differences between groups will be calculated using the log-rank test for univariate analysis. Cox's proportional hazards model will be employed to test independent prognostic factors. All calculations will be performed using the Statistical Package of Social Sciences software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The level of statistical significance will be set at 0.05 for all tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04856137
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Refractory Diffuse Large B-cell Lymphoma
Currently open trials in the same condition.
- NCT06047197 — Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma · Phase 1 · recruiting
Other National Health Research Institutes, Taiwan trials
Trials by the same sponsor.
- NCT07579832 — Quantitative Monitoring of Disability Care Quality for Long-Term Care Facilities 2 · NA · not yet recruiting
- NCT06981637 — Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Contr · Phase 2 · recruiting
- NCT07177365 — Internet-Based Cognitive Behavioral Therapy With Treatment as Usual for Generalized Anxiety Disorder and Major Depressiv · NA · not yet recruiting
- NCT07138261 — Taiwanese Anaplastic Thyroid Cancer Registry · not yet recruiting
- NCT07151365 — Plant-based Diets and Healthy Aging · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04856137 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Health Research Institutes, Taiwan
- Last refreshed: 23 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04856137.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing